In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Still Time To File: Potential NDA/BLA Candidates In Queue For 2014

Executive Summary

Potentially, 38 drugs are in queue to be filed for approval in the US before the year’s end, according to Informa’s BioMedTracker. Which drugs are the most likely candidates?

Advertisement

Related Content

New Molecular Entities Approved In 2014
Biologics Approved In 2014
PCSK9 Meets PRV: Regeneron’s $70 Mil. Bid To Catch Up To Amgen
AstraZeneca’s Gout Drug Lesinurad Hobbled By Renal Risk
New Drugs In 2013 Show A Virtuous Cycle: First-Cycle Approvals Up, Review Times Down

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel